ASTC

Astrotech Corp (ASTC) - 10-Q Summary

Business Context and Reporting Period

This filing is a Quarterly Report on Form 10-Q for the period ended March 31, 2025. Astrotech Corporation (Nasdaq: ASTC) is a Delaware corporation focused on expanding access to mass spectrometry (MS) technology through its "AMS Technology" platform. The company operates through wholly-owned subsidiaries targeting security (1st Detect), agriculture (AgLAB), breath analysis (BreathTech), environmental testing (EN-SCAN), and industrial process control (Pro-Control). The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: All financial figures are in thousands unless otherwise noted. The company reported no long-term debt.

Material Changes vs. Prior Period

• Revenue: Revenue increased by $484,000 (968%) for the three months ended March 31, 2025, compared to the same period in 2024, driven by increased device sales of the TRACER 1000 and a government grant. However, for the nine-month period, revenue decreased by $761,000 (48%) compared to the prior year due to fewer device sales overall.
• Operating Expenses: Total operating expenses increased by $563,000 (15.9%) for the quarter and $1.6 million (14.6%) for the nine-month period. This was primarily due to increased spending on sales consulting, hiring additional employees, and higher R&D costs for contractors and cross-platform technology improvements.
• Liquidity: Cash and cash equivalents decreased by $7.6 million from June 30, 2024, to March 31, 2025, primarily due to funding operating losses. Net cash used in operating activities was $10.6 million for the nine months ended March 31, 2025.
• Customer Concentration: One customer accounted for all revenue in the quarter ended March 31, 2025, and two customers accounted for all revenue in the nine-month period.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• 1st Detect: The TRACER 1000 ETD received a $429,000 purchase order from a TSA contractor in Q3. The company is conducting Stage II field trials with the TSA for air cargo security and has received a DHS R&D contract for next-generation explosives detection.
• AgLAB: Field trials for the AgLAB 1000-D2 in the hemp/cannabis distillation market showed yield improvements of 15% to 30%. A master lease agreement was signed with SC Laboratories for joint marketing.
• BreathTech: The Joint Development Agreement with The Cleveland Clinic Foundation expired on April 30, 2025. Management has determined to deploy capital to other subsidiaries rather than continuing the long-term commercialization of breath analysis for now.
• EN-SCAN: A new subsidiary formed in February 2025 to focus on environmental testing and monitoring solutions.

Risks and Contingencies:

• Supply Chain: The company relies on single-source suppliers for critical components (e.g., specialized cables, pumps), creating vulnerability to supply shortages, price fluctuations, and trade restrictions.
• Liquidity: The company has an accumulated deficit of $247.9 million and continues to incur net losses. Continued funding of operations depends on available cash, short-term investments, and potential future financing.
• Regulatory: Success depends on regulatory approvals (e.g., TSA certification) and government funding stability. Changes in trade policy and tariffs could increase costs.

Key Facts for Investor Verification

• Cash Burn Rate: Verify the sustainability of the current cash position ($2.8M cash + $18.1M short-term investments) against the quarterly burn rate of approximately $3.6M in net loss and $10.6M in operating cash outflow over nine months.
• Revenue Concentration: Confirm the identity and stability of the single customer responsible for 100% of Q3 revenue and the two customers responsible for 100% of YTD revenue.
• TSA Certification Status: Monitor the progress of the TRACER 1000 through TSA Stage II testing and the potential for inclusion on the "qualified" list, which is critical for large-scale U.S. government sales.
• Stock-Based Compensation: Note that stock-based compensation was $152,000 for the quarter and $629,000 for the nine months, with significant future recognition remaining ($973k for options, $317k for restricted stock).
• Valuation Allowance: The company maintains a full valuation allowance against all net deferred tax assets due to cumulative losses, resulting in a 0% effective tax rate.